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The publication of the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines
on the treatment of glomerular diseases in 2012 marked a milestone in this ﬁeld, as it is
the ﬁrst time that comprehensive guidelines are provided for such disease entities. The
current review focuses on major ﬁndings, both pathogenesis related and clinical, in the
primary glomerulonephritis that have been made after the guidelines came into effect.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Certainly the most important event in 2012 was the pub-
lication of the Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines for the treatment of glomerular diseases
[1]. For the ﬁrst time evidence-based guidelines are now
available in this ﬁeld. The guidelines have taken a relatively
long time to be published and are based on the knowledge
available in early 2011 to mid-2011. Thus, in this review I will
focus exclusively on important developments in the ﬁeld of
primary glomerulonephritis (GN) in 2012 and early 2013.
Immunoglobulin A nephropathy
Pathogenesis
The year 2012 has seen some advances in understanding
the complex pathogenesis of immunoglobulin A nephropathy
(IgAN) [2–4]. There is increasing evidence that autoantibodies
play a role against poorly galactosylated IgA in the disease.
These autoantibodies are largely conﬁned to IgAN and corre-
late with the clinical prognosis [5,6]. Poor galactosylation of
the circulating (and deposited) IgA may, among others, involve
altered expression of miR-148b [7]. In addition, a recent studyn Society of Nephrology. Publi
c-nd/4.0/).
achen, Medizinische
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e (J Floege)suggests that the fractalkine CX3CR1 contributes to the char-
acteristic hematuria seen in IgAN [8], but the exact mechanism
by which it may cause hematuria still remains elusive [9].
In an elegant mouse model, the role of the two IgA
receptors, soluble CD89 (sCD89) and transferrin-receptor-1,
was studied [10]. Mice with transgenic overexpression of
human IgA1 and CD89 develop inﬂammatory renal changes,
hematuria, and proteinuria. In these mice, sCD89 binds
mesangial transferrin-receptor-1 and this complex induces
transglutaminase-2 in the cells. The latter serves as an ampli-
ﬁcation loop, favoring the generation of more IgA1-sCD89
complexes and thus further activation of mesangial cells.
Transglutaminase-2 thus may be a novel therapeutic target
in IgAN, provided that this mechanism can be conﬁrmed in the
human disease.
Another rapidly evolving area is the knowledge on the
genetic basis of IgAN in large populations. Genome-wide
association studies have identiﬁed associations of single
human leukocyte antigen (HLA) polymorphisms [11] and some
proinﬂammatory genes [12] with the development or course
of IgAN. More importantly, using such a genetic approach, we
can develop a worldmap of IgAN risk [13] (Fig. 1).
Prognosis
As previously done, in 2011, a number of studies attempted
to validate the histological Oxford classiﬁcation of IgAN [14].
Similar to previous studies, the more recent ones again show
that mainly interstitial changes (i.e., the “T” criterion of theshed by Elsevier. This is an open access article under the CC BY-NC-ND
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Figure 1. World-wide genetic risk for immunoglobulin A nephropathy (IgAN). Gene-wide association studies indicate different worldwide risks
for IgAN. (Reprinted with permission from Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F,
Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A,
Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib
HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG. Geographic differences in genetic
susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8:e1002765, 2012)
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all other parameters, in particular the more inﬂammatory
changes (“M” and “E”) performed less reliably ([15–20],
Table 1). Similarly, the presence of glomerular crescents, which
is not a part of the four Oxford criteria, is of inconsistent
prognostic power.
Apart from histological predictors of IgAN, a Korean study
demonstrated that low circulating C3 levels can also herald an
adverse prognosis in IgAN patients [21]. Similarly, extraglo-
merular C3 deposits in Bowman's capsule and/or arterioles
signal an adverse prognosis [22].
Of clinical importance is a Chinese study that describes
histological features of 90 IgAN patients, who had received a
kidney biopsy for isolated microhematuria [23]. Not surpris-
ingly, these patients exhibited mostly mesangial hypercellu-
larity (“M” in the Oxford classiﬁcation) and endocapillary
proliferation (“E” in the Oxford classiﬁcation), i.e., mostly early
and inﬂammatory changes. However, and very remarkably,
within these relatively young patients (mostly 20–30 years
old) 50% had some focal or global glomerulosclerosis, 20% had
tubulointerstitial damage, and 25% had isolated glomerular
crescents. Thus, the important insight gained here is that IgAN
patients with a clinically excellent prognosis can exhibit even
crescents and vice versa; not every crescent in IgAN necessi-
tates immunosuppression.
Clinical aspects
A Spanish study reported on the long-term course of 141
IgAN patients, who, similar to the Chinese patients discussed
earlier, had received kidney biopsies despite only minor
urinary abnormalities [i.e., microhematuria or mild proteinuriawith a normal glomerular ﬁltration rate (GFR)] [24]. No patient
received immunosuppression. An increase in serum creatinine
of 50% or more was observed in 3.3% of cases at 10 years
follow-up and in 8.9% of cases at 20 years follow-up. Of the
patients, 38% developed a full clinical remission after a median
duration of 48 months. However, six patients developed a
proteinuria of more than 1 g/d and 42% of patients subsequently
received blockers of the renin–angiotensin system (RAS).
This Spanish study therefore conﬁrms that mild IgAN has
an excellent overall prognosis. However, a few patients will
progress, and currently it is not possible to identify them
prospectively. It is therefore imperative that such early diag-
nosed IgAN patients receive annual or biannual checkups.
Based on the literature, a nephrotic syndrome is a rare
manifestation of IgAN (unless there is an overlap with minimal
change nephropathy). It is therefore notable that in Korea
about 10% of a large patient series exhibited a nephrotic
syndrome [25]. Such patients had a poor prognosis, and almost
a quarter of them experienced a doubling of their serum
creatinine within the subsequent 4 years. Surprisingly, how-
ever, others exhibited spontaneous remissions, a good prog-
nosis (in particular women and patients with low initial serum
creatinine levels, and a decrease of the proteinuria of 450% in
3 months). Again, these observations stress the importance of
regular controls after the diagnosis.
Yet another Korean study contradicts the widespread opi-
nion that Henoch-Schönlein purpura in adults runs a more
severe course than primary IgAN [26]: when patients were
matched for baseline characteristics, the course of the two
diseases was not different. This study supports the general
assumption that the two diseases are very similar and likely
manifestations of the same disease process.
Table 1. Recent studies on the validation of the Oxford classiﬁcation of immunoglobulin A nephropathy
Ref. Country n Independent prognosis predictors Comments
[15] China 1,026 M, T Crescents without prognostic relevance
[16] China 218 (children) T Crescents without prognostic relevance
[17] Korea 69 E, T
[18] Sweden 99 (children) M, E, T Crescents with prognostic relevance,
but only univariate analysis
[19] Korea 197 T
[20] Japan 161 (children) M, T Crescents with prognostic relevance
E, endocapillary proliferation; M, mesangial hypercellularity; S, glomerulosclerosis; T, tubular atrophy and interstitial ﬁbrosis.
AKI due to
macrohematuria or
other common cause
Optimize supportive therapy
for 3-6 months
Nephrotic syndrome
or
Crescentic GN with
RPGN-course
Low Risk
(isolated microhematuria ± proteinuria <0.5 g/d, 
GFR normal, no hypertension)
Intermediate Risk
(proteinuria >0.5-1 g/d ± GFR reduced ± 
hypertension)
Annual or bi-annual monitoring 
for at least 10 years
High Risk
(acute or rapid loss of GFR) 
Supportive therapy
GFR >50 ml/min GFR 30-50 ml/min GFR ≤30 ml/min 
Proteinuria
<1 g/day
and GFR 
stable
Continue
supportive
therapy
Proteinuria
≥1 g/day
and/ or GFR 
decline*
+ add 6 month
course of
cortico-steroid 
(see text)
Continue
supportive
therapy
Continue supportive therapy
No immunosuppression (except
if RPGN)
Continue supportive therapy
Value of immunosuppression 
unknown. Critically weigh pro 
and con (see text) 
+ add immuno-
suppression (see
text)
Continue supportive
therapy
Figure 2. Therapy algorithm for immunoglobulin A nephropathy. Details of the suggested supportive therapy can be found in [28]. AKI, acute
kidney injury; RPGN, rapidly progressive glomerulonephritis. Modiﬁed from [28].
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We have summarized the therapy of IgAN recently (Fig. 2)
[27,28].
A new study from Hong Kong assessed the effects of low-
dose angiotensin-converting enzyme (ACE) inhibitors in early
IgAN [29]. Sixty patients with a proteinuria ofo0.5 g/d,
normotension, and a normal GFR received 2.5 mg/d ramipril
or no speciﬁc therapy. After 5 years, there were no differences
between the groups and GFR loss was almost identical (−0.47
2.6 mL/min/1.73 m2 per year vs. −0.671.6 mL/min/1.73 m2 per
year). It is very likely that the study was underpowered in
view of the very slow progress of early IgAN and thus the
study cannot ﬁnally answer whether such early IgAN patients
beneﬁt from RAS blockade in the very longterm.
Japanese authors continue to report on the success of
tonsillectomy in IgAN [30–33]; however, a large randomizedtrial is still to be performed, and KDIGO, at present, does not
recommend routine tonsillectomies in IgAN [1].
Corticosteroids and other immunosuppressive drugs
A meta-analysis investigated the value of corticosteroid
therapy in IgAN. The study concluded that corticosteroids
can retard the progress of renal failure and can reduce
proteinuria [34]. Low doses (o30 mg/d prednisone initially)
are ineffective. The meta-analysis, however, also concludes
that the methodological quality of available studies is low.
Consequently, steroids should only be used in IgAN when
supportive measures have failed (Fig. 2).
An uncontrolled Korean case series reported on 22 IgAN
patients with a median eGFR of 34 mL/min/1.73 m2 [2,35]. In
the KDIGO guidelines such patients represent a dilemma,
because other than optimizing the supportive therapy no
Kidney Res Clin Pract 32 (2013) 103–110106recommendations are given, as literally all randomized trials
so far have excluded such patients. All Korean patients
received a RAS blocker followed by 500 mg methylpredniso-
lone i.v. every 2nd week for 6 months. Although this did not
improve proteinuria, it did slow down the loss of GFR.
Reportedly there were no relevant side effects.
Other uncontrolled reports describe the use of tacrolimus in
“refractory IgAN” [36], where 20% of the patients experienced
a decline of GFR but in 80% of patients proteinuria was
lowered, as well as combined prednisolone and mycopheno-
late mofetil (MMF) therapy, which reduced proteinuria but did
not affect serum creatinine [37]. Unfortunately, these uncon-
trolled studies do not help in deciding which therapy is
effective in patients with IgAN. At present, KDIGO guidelines
recommend neither tacrolimus nor MMF in IgAN.
Two ongoing randomized controlled trials assess the value of
corticosteroids added to optimized supportive care: Our sup-
portive versus immunosuppressive therapy of progressive IgA
nephropathy (STOP-IgAN) trial [38], whichwill end in late 2014,
and the large therapeutic evaluation of steroids in IgA nephro-
pathy global study (TESTING study), which just started in China
and Australia (NCT01560052). Another trial that has started is
the pan-European NEFIgAN study, where patients will receive
budenoside or placebo based on a Swedish pilot study [39].
Membranous glomerulonephritis
Pathogenesis
Autoantibodies against phospholipase-A2-receptor (PLA2R-Ab),
mostly of the IgG4 class (rarely monoclonal IgG3 [40]), can be
found in about 70% of all patients with primary membranous
GN. They bind to PLA2R on podocytes with the in situ formation
of immune complexes and complement activation [41,42]. In
addition to these autoantibodies, further autoantigens are being
searched for in membranous GN. An Italian group repeatedly
described IgG4 autoantibodies against aldose-reductase, super-
oxid-dismutase-2, and alpha-enolase in patients with membra-
nous GN [43]. These antibodies occurred at lower frequency
compared to PLA2R-Ab. Their pathogenetic importance remainsFigure 3. Therapy algorithm for membranous nephropathy. For details of
2012 guidelines [1]. AKI, acute kidney injury; KDIGO, Kidney Disease: Improunclear at present, because the corresponding antigens are not
found in podocytes in membranous GN (in contrast to PLA2R,
which is expressed de novo). Another potential autoantigen is
synaptonemal complex protein 65 (SC65) [44].
Clinical aspects
Dutch data show a close correlation between PLA2R-Ab
levels with the clinical course (i.e., disappearance of the
autoantibodies during clinical remission) and proteinuria
[42]. The potential clinical use of detecting PLA2R-Ab rests in
the serologic diagnosis of a primary membranous GN, ther-
apeutic stratiﬁcation, and therapy monitoring. The antibodies
may also aid in the differentiation between primary and
secondary GN: in secondary membranous GN both circulating
antibodies and PLA2R expression on podocytes are generally
absent, although there are rare exceptions to this rule [45].
Detection of PLA2R autoantibodies in the circulation and
PLA2R expression on podocytes is mostly concordant, and
possibly the demonstration of PLA2R on podocytes is more
sensitive [46]. It is presently unknown whether therapeutic
decisions can be based on the course of PLA2R-Ab.
From a clinical point of view, a Spanish study is important,
which demonstrates that even in patients with impaired renal
function, spontaneous remissions are possible if only RAS-
blockers are given [47].
Therapy
Sixteen years after its initiation, a British randomized trial
in membranous GN was ﬁnally published in 2012 [48]. In this
study, high-risk patients with membranous GN (i.e., those with
a relatively rapid decline in GFR) were randomized to suppor-
tive therapy only (n¼38), prednisone and chlorambucil
(n¼33), or cyclosporine (n¼37). Only prednisone/chlorambu-
cil lowered the risk of progression, although even this group
continued to lose some GFR. Cyclosporine was not effective in this
selected group of patients and was not different from supportive
therapy only. Not unexpectedly, the combination therapy caused
more adverse effects. Unfortunately, prednisone/chlorambucil isthe suggested immunosuppressive approach, please refer to the KDIGO
ving Global Outcomes; NS, nephrotic syndrome.
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cyclophosphamide. We can only assume that this combination is
equally effective in these high-risk patients.
In 2012, the Italian group from Bergamo published its
experience with 100 consecutive membranous GN patients
treated with rituximab [49]. After a median 29-month follow-
up, 65% exhibited partial or full remission, 4% were on dialysis,
and 4% had died (of unrelated causes, according to the
authors). Having had a prior immunosuppressive therapy
was a key predictor for failure to respond to rituximab.
Unfortunately, there is no information on whether the pre-
sence or absence of PLA2R-Ab also inﬂuenced rituximab
responses.
At present, KDIGO still recommends a cyclophosphamide-
or alternatively a calcineurin inhibitor-based ﬁrst-line therapy,
whereas MMF or a corticosteroid monotherapy are not sug-
gested [1] (Fig. 3). Rituximab is still considered a second-line
therapy. This view has also been shared by a very recent
editorial, which, apart from the considerable cost associated
with rituximab therapy, points out the risks of the rare
progressive multifocal leukoencephalopathy and also notes
that at least in a vasculitis study rituximab-treated patients
exhibited an increased tumor risk [50]. Finally, rituximab can
induce a hypogammaglobulin syndrome independently of the
dose, which manifests similar to a chronic immune deﬁciency
syndrome and may not be reversible. A prior immunosuppres-
sive therapy may increase the risk for this latter complication.
Nevertheless, others also caution against too much rituximab
euphoria and demand controlled clinical trials [51,52]. Indeed,
a controlled trial comparing cyclosporine versus rituximab in
membranous GN is underway (NCT01180036).Minimal change nephropathy and focal segmental
glomerulosclerosis
Pathogenesis
A central discovery of the past years was the demonstration
of elevated soluble urokinase receptor (suPAR) levels in the
serum of focal segmental glomerulosclerosis (FSGS) patients
[53]. The pathophysiological basis of how suPAR relates to
nephrotic syndrome is well documented, and indeed suPAR
transgenic animals developed FSGS.
Etiology and prognosis
The group that discovered suPAR in FSGS has now validated
their ﬁndings in two large cohorts of 164 children and adults
with primary FSGS [54]. Of the patients studied, 84% of the
children and 55% of the adults exhibited elevated suPAR levels
in their circulation. However, suPAR levels in the circulation also
increase nonspeciﬁcally in chronic kidney disease (CKD) due to
renal retention. Another puzzling ﬁnding of that study is that
FSGS patients with mutations of NPHS2 exhibited even higher
suPAR levels than nongenetic FSGS cases. Finally, the ﬁrst
studies where the difference between suPAR levels in primary
FSGS versus secondary FSGS or other glomerular diseases was
not conﬁrmed are emerging [55]. Thus, still much has to be
learned about suPAR prior to recommending this as a routine
clinical assessment or even as a therapeutic target in FSGS cases.
As to genetic causes of FSGS, the role of mutations in inverted
formin 2 (INF2) as a cause of familial autosomal-dominant FSGSwas better established in 2012 [56–58]. Nevertheless, the KDIGO
guidelines still do not recommend routine screening for muta-
tions in podocyte proteins in adults with FSGS as long as no
family history is present. Indeed, in 26 consecutive German
dialysis patients with underlying FSGS, mutations were detected
only in 8% of patients and were found in TRPC6, ACTN4, NPHS2,
and NPHS1 with no mutations in INF2, CD2AP, and WT1) [59].
This was conﬁrmed in another large cohort of sporadic FSGS
patients, where INF2 mutations were found in less than 1% of
patients [56].
A clinically important issue is the distinction between
minimal change nephropathy and FSGS, in particular if the
latter is in an early stage. Possibly, an activation marker in
glomerular parietal epithelial cells, which was discovered by
us, can help in this respect [60]; at least in renal transplant
biopsies the immunohistological detection of CD44 on parietal
epithelium allowed a reliable distinction.Therapy
Few studies have been reported in 2012 on the treatment of
minimal change nephropathy or FSGS: (1) in an Indian study,
131 children with steroid resistance received either 12 months
of tacrolimus or 6 months of i.v. cyclophosphamide boli plus
steroids [61]. Compared to cyclophosphamide, tacrolimus
induced more complete remissions (52% vs. 15%, respectively)
and led to fewer adverse effects; (2) in a German trial, 23
children with FSGS were analyzed after induction of remission
by steroid boli plus cyclosporine [62]. The subsequent main-
tenance therapy included alternating steroid, cyclosporine,
and RAS blockers. MMF was subsequently used in 18 of the
children. All were maintained in remission for 47 years, and
in 30% of patients all immunosuppressants could be stopped.
There were ﬁve relapses in the 23 patients, all of which
responded well to repeated therapy. The authors conclude
that MMF is a potent maintenance therapy in FSGS; and ﬁnally
(3) a French study described the course of 17 adults with
steroid-dependent minimal change nephropathy following
the administration of rituximab [63]. All had previously
failed other immunosuppressive approaches. Eleven of the 17
patients subsequently had no more relapses after rituximab,
and nine could halt all immunosuppressants. Others were at
least able to reduce their dose of immunosuppressants. There
were no serious adverse effects. The reason why rituximab
worked in a disease not considered to be mediated by B cells
currently remains elusive.Other primary GN
Membranoproliferative glomerulonephritis
A single case of cryoglobulinemia-triggered membranopro-
liferative glomerulonephritis was described, and the patient
responded well to imatinib [64].
Dense deposit disease (formerly called
“membranoproliferative glomerulonephritis type II”)
and C3 nephropathy
Following the discovery that dense deposit disease (DDD)
results from unregulated complement activation via an alternative
Kidney Res Clin Pract 32 (2013) 103–110108pathway (mostly from C3 nephritis factor, i.e., C3-activating
autoantibodies) [65], new therapeutic approaches have been
developed for DDD. Already, single patients have received a C5
antibody, eculizumab, every other week for 1 year or longer. In
some of these patients, but not all, clinical and/or histological
manifestations of the disease have improved [66,67]. A ﬁrst case
report also describes the successful use of eculizumab in recurrent
DDD after renal transplantation [68]. However, a concern for
prolonged eculizumab therapy in DDD and C3 GN was raised
when such patients received a second kidney biopsy after 1 year
of treatment; whereas glomeruli in these diseases typically con-
tained only C3 deposits but no Igs at baseline, after 1 year of
treatment there was prominent deposition of IgG2 and IgG4 as
well as IgG-kappa light chain, all components of the eculizumab
molecule [69]. This deposition was histologically very similar to
the disease entity known as monoclonal IgG deposition disease.
Long-term consequences of these pathological changes are cur-
rently unknown.
Following the ﬁrst description of C3 nephropathy in
patients with an autosomal-dominant mutation in the CFHR5
gene, further characteristics have been reported [70]. So far,
the disease has only been described in patients originating
from Cyprus; possibly all cases can be traced to a small
mountain area. Histologically, the central ﬁnding is prominent
glomerular C3 deposition with no immune complexes, obviously
due to the unregulated complement activation. About 50% of the
affected individuals, in particular men, develop renal failure.Postinfectious GN
Postinfectious GNs mostly heal with no long-term sequelae.
A small percentage of affected patients, however, develop a
course of progressive CKD. In a report from the Mayo Clinic, it
has now been proved that such patients exhibit defects in the
regulation of the alternative complement pathway (e.g., muta-
tions in complement-regulatory proteins, C3 nephritis factor,
and others) [71].Conﬂicts of interest
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